DIGIPREDICT proposes the first of its kind digital twin to predict the progression of disease and the need for early intervention in infectious and cardiovascular diseases.
A digital twin is a digital representation of an object or process from the real world in the digital world – and more specifically for the case of DIGIPREDICT – of a patient. The DIGIPREDICT digital twins will be used ‘at the edge’, e.g. at the hospital level.
The project combines the latest advances in digital biomarkers, organ-on-chip (OoC) and artificial intelligence (AI) at the edge, and aims to build a new interdisciplinary community in Europe focused on digital twins.
The developed system will provide medical doctors with a unique digital tool for early prediction of potential serious complications in COVID-19 patients. Beyond COVID-19, the system promises to also improve the prevention, diagnosis, monitoring and treatment of cardiovascular disease and detect the potential onset of inflammatory disease.
The DIGIPREDICT consortium is composed of seven top-level universities, research centres, hospitals and three SMEs bringing together a range of excellent international scientists with complementary and interdisciplinary skills. Together, they combine cross-cutting lines of research in all aspects of intelligent systems with latest advances in biomedical research.